IMcoMET is a MedTech startup, offering a new source of biomarkers through their M-Duo Technology®. This innovation allows access and control of interstitial fluid, providing valuable biomarkers for assessing tissue condition and overall health. With a focus on improving skin cancer diagnostics and research, IMcoMET drives personalized medicine and biomedical research to enhance therapy outcomes for skin cancer patients. Founded in 2018, IMcoMET operates in the Biopharma, Biotechnology, and Pharmaceutical industries.
Imcomet
Access a new source of biomarkers
Founded 2018
The Netherlands
5 employees
Biopharma, Biotechnology +1
The Netherlands
5 employees
Biopharma, Biotechnology +1
General Information
Company Name
Imcomet
Founded Year
2018
Location
The Netherlands
The Netherlands
Employees
5
Industries
Biopharma, Biotechnology, Pharmaceutical
BounceWatch is an independent company data service, not affiliated with Imcomet. To contact Imcomet, visit imcomet.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Imcomet compare?
A PDF of Imcomet and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Imcomet soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
The Netherlands Market
Biopharma
About Imcomet
Business keywords: MedTech, biomarker technology, M-Duo Technology®, fluid analysis, cancer diagnostics, personalized medicine, biomedical research, therapy outcomes, skin cancer, interstitial fluid, biomarker analysis, diagnostic tools, oncology research, precision medicine
No funding data available for Imcomet yet.
Imcomet Alternatives & Competitors
View All Alternatives
Imcomet vs
Theramir Ltd
Cyprus
Developing novel microRNA based therapeutics and companion diagnostics for patients and healthcare p...
8 employees
Biopharma, Biotechnology
Imcomet vs
Viracta Therapeutics, Inc.
United States
A precision oncology company focused on the treatment and prevention of virus-associated cancers tha...
IPO
31 employees
Biopharma, Biotechnology
Imcomet vs
Inoviv
United Kingdom
Accelerating the Development of New Medicines with Targeted Proteomics
Venture round
34 employees
Biopharma, Biotechnology
FAQ About Imcomet
Access a new source of biomarkers
Imcomet was founded in 2018.
Imcomet is headquartered in The Netherlands.
Imcomet operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on MedTech, biomarker technology, M-Duo Technology® and fluid analysis.
Imcomet has approximately 5 employees.
Top alternatives and competitors to Imcomet include Theramir Ltd, Viracta Therapeutics, Inc., Inoviv, Lantern Pharma Inc. (Nasdaq: LTRN), OncoHost. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Imcomet and Theramir Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Imcomet, https://bouncewatch.com/company/imcomet, updated 25 September 2026. When citing, please name BounceWatch and link this page.
